OPUS GENETICS INC. - COMMON STOCK

Ocuphire to Participate in March Investor Conferences

04 3 2021 08:27:09 提供 Nasdaq GlobeNewswire

Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia

18 2 2021 08:53:31 提供 Nasdaq GlobeNewswire

Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021

11 2 2021 09:12:54 提供 Nasdaq GlobeNewswire

Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase

20 1 2021 07:00:00 提供 Nasdaq GlobeNewswire

Ocuphire Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

06 1 2021 07:00:01 提供 Nasdaq GlobeNewswire